RxDoctor Payments Data

Anjali Sharma, MD

Cardiovascular Disease · Hartford, CTNPI 1659787125

Payments from drug & device makers

$4,639in general payments, 2019–2025

Across 104 payments — averaging $44.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$685
  • Edwards Lifesciences$351
  • Novartis$345
  • E.r. Squibb & Sons, L.L.C.$211
  • Astellas Pharma US Inc$100
  • plus $366 from 9 others

What the payments were for

  • Travel & lodging$1,44431%
  • Food & beverage$3,09567%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,639 in reported general payments places this provider in the 70th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$95,155
Medicare patients
684
Services billed
1,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban111$75,021
Repatha SureclickEvolocumab32$22,393
EntrestoSacubitril/Valsartan18$18,342
JardianceEmpagliflozin15$9,708
XareltoRivaroxaban15$7,962
FarxigaDapagliflozin Propanediol11$6,522
Rosuvastatin Calcium231$2,563
Ranolazine ErRanolazine27$1,821
Metoprolol Succinate151$1,408
Metoprolol Tartrate96$949
Potassium Chloride69$653
Torsemide20$602
Ezetimibe39$524
Spironolactone50$469
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide12$441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$75,021111 claims
NovartisEntresto$345$18,34218 claims
Johnson & JohnsonXarelto$52$7,96215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →